TISIDB

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell junction, focal adhesion Cell junction, adherens junction Cell membrane Peripheral membrane protein Endoplasmic reticulum membrane Peripheral membrane protein Nucleus Melanosome Cytoplasm, cytosol Cytoplasm, cytoskeleton Secreted, exosome Membrane raft Note=Mainly membrane-associated. Localized to adherens junctions, focal adhesions and endoplasmic reticulum. Colocalized with actin stress fibers. Also found in the nucleus. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2) (PubMed:27386966).
Domain	PF00595 PDZ domain (Also known as DHR or GLGF)
Function	Multifunctional adapter protein involved in diverse array of functions including trafficking of transmembrane proteins, neuro and immunomodulation, exosome biogenesis, and tumorigenesis (PubMed:26291527). Positively regulates TGFB1-mediated SMAD2/3 activation and TGFB1-induced epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types. May increase TGFB1 signaling by enhancing cell-surface expression of TGFR1 by preventing the interaction between TGFR1 and CAV1 and subsequent CAV1-dependent internalization and degradation of TGFR1 (PubMed:25893292). In concert with SDC1/4 and PDCD6IP, regulates exosome biogenesis (PubMed:22660413). Regulates migration, growth, proliferation, and cell cycle progression in a variety of cancer types (PubMed:26539120). In adherens junctions may function to couple syndecans to cytoskeletal proteins or signaling components. Seems to couple transcription factor SOX4 to the IL-5 receptor (IL5RA) (PubMed:11498591). May also play a role in vesicular trafficking (PubMed:11179419). Seems to be required for the targeting of TGFA to the cell surface in the early secretory pathway (PubMed:10230395).

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0001837 epithelial to mesenchymal transition GO:0002090 regulation of receptor internalization GO:0002091 negative regulation of receptor internalization GO:0006612 protein targeting to membrane GO:0006887 exocytosis GO:0006898 receptor-mediated endocytosis GO:0006929 substrate-dependent cell migration GO:0006930 substrate-dependent cell migration, cell extension GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007179 transforming growth factor beta receptor signaling pathway GO:0007254 JNK cascade GO:0007265 Ras protein signal transduction GO:0007346 regulation of mitotic cell cycle GO:0009894 regulation of catabolic process GO:0009895 negative regulation of catabolic process GO:0010498 proteasomal protein catabolic process GO:0010717 regulation of epithelial to mesenchymal transition GO:0010718 positive regulation of epithelial to mesenchymal transition GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0016049 cell growth GO:0016050 vesicle organization GO:0017015 regulation of transforming growth factor beta receptor signaling pathway GO:0017157 regulation of exocytosis GO:0030031 cell projection assembly GO:0030100 regulation of endocytosis GO:0030307 positive regulation of cell growth GO:0030335 positive regulation of cell migration GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway GO:0031098 stress-activated protein kinase signaling cascade GO:0031329 regulation of cellular catabolic process GO:0031330 negative regulation of cellular catabolic process GO:0031623 receptor internalization GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0040017 positive regulation of locomotion GO:0042176 regulation of protein catabolic process GO:0042177 negative regulation of protein catabolic process GO:0043112 receptor metabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043410 positive regulation of MAPK cascade GO:0044089 positive regulation of cellular component biogenesis GO:0045806 negative regulation of endocytosis GO:0045861 negative regulation of proteolysis GO:0045921 positive regulation of exocytosis GO:0045927 positive regulation of growth GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0048013 ephrin receptor signaling pathway GO:0048259 regulation of receptor-mediated endocytosis GO:0048261 negative regulation of receptor-mediated endocytosis GO:0048762 mesenchymal cell differentiation GO:0051047 positive regulation of secretion GO:0051051 negative regulation of transport GO:0051272 positive regulation of cellular component movement GO:0051403 stress-activated MAPK cascade GO:0060389 pathway-restricted SMAD protein phosphorylation GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation GO:0060485 mesenchyme development GO:0060627 regulation of vesicle-mediated transport GO:0061136 regulation of proteasomal protein catabolic process GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0071971 extracellular exosome assembly GO:0072657 protein localization to membrane GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090150 establishment of protein localization to membrane GO:0090287 regulation of cellular response to growth factor stimulus GO:1901799 negative regulation of proteasomal protein catabolic process GO:1902115 regulation of organelle assembly GO:1902117 positive regulation of organelle assembly GO:1903050 regulation of proteolysis involved in cellular protein catabolic process GO:1903051 negative regulation of proteolysis involved in cellular protein catabolic process GO:1903362 regulation of cellular protein catabolic process GO:1903363 negative regulation of cellular protein catabolic process GO:1903532 positive regulation of secretion by cell GO:1903541 regulation of exosomal secretion GO:1903543 positive regulation of exosomal secretion GO:1903551 regulation of extracellular exosome assembly GO:1903553 positive regulation of extracellular exosome assembly GO:1903844 regulation of cellular response to transforming growth factor beta stimulus GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus GO:1990182 exosomal secretion GO:2000147 positive regulation of cell motility
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0001948 glycoprotein binding GO:0005109 frizzled binding GO:0005126 cytokine receptor binding GO:0005137 interleukin-5 receptor binding GO:0008022 protein C-terminus binding GO:0008093 cytoskeletal adaptor activity GO:0019838 growth factor binding GO:0030674 protein binding, bridging GO:0042043 neurexin family protein binding GO:0045296 cadherin binding GO:0045545 syndecan binding GO:0046875 ephrin receptor binding GO:0046982 protein heterodimerization activity GO:0047485 protein N-terminus binding GO:0050839 cell adhesion molecule binding GO:0060090 binding, bridging GO:0070851 growth factor receptor binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005895 interleukin-5 receptor complex GO:0005913 cell-cell adherens junction GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0042470 melanosome GO:0043235 receptor complex GO:0045121 membrane raft GO:0048770 pigment granule GO:0072562 blood microparticle GO:0098589 membrane region GO:0098802 plasma membrane receptor complex GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928664: Ephrin signaling R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-373760: L1CAM interactions R-HSA-447043: Neurofascin interactions R-HSA-6798695: Neutrophil degranulation

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SDCBP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SDCBP and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29845474	Triple-Negative Breast Carcinoma	Inhibit immunity	Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1. Western blot and flow cytometry analyses demonstrated that syntenin1 induced CD8+ T cell apoptosis in vitro and in vivo through upregulating PD-L1.

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SDCBP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SDCBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.076	0.863
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.115	0.977
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.041	0.988
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.173	0.696
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.732	0.687
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.532	0.814
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.373	0.54
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.727	0.792
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.102	0.975
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.723	0.736
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.185	0.729
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.075	0.37

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SDCBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	0	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	0	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SDCBP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SDCBP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SDCBP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SDCBP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SDCBP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SDCBP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SDCBP
Name	syndecan binding protein (syntenin)
Aliases	SYCL; MDA-9; MDA9; ST1; TACIP18; melanoma differentiation associated protein-9; melanoma differentiation-ass ......
Chromosomal Location	8q12.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SDCBP collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SDCBP